Terumo (OTCMKTS:TRUMY) Rating Increased to Strong-Buy at Nomura

Terumo (OTCMKTS:TRUMY) was upgraded by investment analysts at Nomura from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Separately, Zacks Research raised Terumo to a “hold” rating in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Terumo Trading Down 4.0%

Shares of TRUMY stock opened at $14.53 on Thursday. Terumo has a 12-month low of $12.08 and a 12-month high of $19.60. The company has a current ratio of 1.59, a quick ratio of 0.97 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $14.01 and its 200 day moving average is $13.54. The stock has a market capitalization of $21.43 billion, a P/E ratio of 23.82 and a beta of 0.68.

Terumo (OTCMKTS:TRUMY) last posted its earnings results on Friday, May 15th. The company reported $0.11 EPS for the quarter, hitting analysts’ consensus estimates of $0.11. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.84 billion. Terumo had a net margin of 12.09% and a return on equity of 9.17%. Research analysts expect that Terumo will post 0.7 earnings per share for the current year.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.